Lab worker inspecting a tube
Lab worker inspecting a tube

EHA 2022


09 - 12

Jun 2022

EHA 2022

Vienna, Austria

European-based organization and congress promoting excellence in hematology.


  • Oral Presentation

    Single-cell RNA Profiling of Myelofibrosis Patients Reveals Pelabresib-Induced Decrease of Megakaryocytic Progenitors and Normalization of CD4+ T cells in Peripheral Blood

  • Oral Presentation

    BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis — JAK Inhibitor-Naïve or With Suboptimal Response to Ruxolitinib Preliminary Data From the MANIFEST Study

  • Poster

    Matching-Adjusted Indirect Comparison (MAIC) of Pelabresib in Combination With Ruxolitinib vs Janus Kinase Inhibitors in Patients with Myelofibrosis

  • Poster

    MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs Placebo and Ruxolitinib in JAK Inhibitor-Naïve Myelofibrosis Patients


ASCO 2022

Annual meeting featuring presentations on the latest research in cancer care.

03/06 - 07/06 Chicago, IL

SOHO 2022

Annual meeting of global society of clinicians and scientists specializing in hematology.

28/09 - 01/10 Houston, TX

ASH 2022

World’s largest network supporting clinical and scientific hematology research.

10/12 - 13/12 New Orleans, LA

MorphoSys is providing the data presented at medical congresses as part of scientific exchange. The scientific information may include data/information on investigational use(s) of compounds/drugs of which the efficacy and safety have not yet been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of MorphoSys’ products. Copies of congress presentations may not be reproduced without written permission from the congress and the authors.